BioSpace News Archive

Drug Development

Frequency Therapeutics Completes Enrollment in Single Dose Safety Trial to Evaluate FX-322, a First-in-Class Drug Candidate for Hearing Restoration

Frequency Therapeutics today announced the completion of enrollment in the single dose safety trial to evaluate FX-322, a first-in-class drug candidate for hearing restoration from the company’s Progenitor Cell Activation (PCA) Regeneration platform.

October 4, 2018
·
4 min read
Deals

SAIC Declares Quarterly Cash Dividend Payable on October 26, 2018

Science Applications International Corporation announced today that its Board of Directors has authorized and declared a regular quarterly cash dividend of $0.31 per share.

October 4, 2018
·
1 min read
FDA

Allergan Receives FDA Clearance To Treat Area Below The Jawline With CoolSculpting®

FDA clearance was expanded to include patients with a BMI of up to 46.2 when treating the submental and submandibular areas.

October 4, 2018
·
6 min read
Deals

Tauriga Sciences Inc. Enters into MOU to Acquire California Based Revenue Generating OMEGA-3 Product and Technology

This MOU, executed on October 3, 2018 , is valid for a period of 45 days and closing is subject to satisfactory completion of due diligence by all parties.

October 4, 2018
·
5 min read
Business

LONG ISLAND PLASTIC SURGICAL RESIDENTS PRESENT AT THE AMERICAN SOCIETY OF PLASTIC SURGEON’S ANNUAL MEETING IN CHICAGO

Long Island Plastic Surgical Group (LIPSG) is proud to announce that a group of doctors from its Residency Program were selected to give 7 presentations at the meeting of the American Society of Plastic Surgeons (ASPS) in Chicago.

October 4, 2018
·
3 min read
Genetown

Momenta Pharmaceuticals to Host R&D Day on October 11, 2018

Momenta Pharmaceuticals, Inc. today announced that it will host a live webcast of its R&D Day on Thursday, October 11, 2018 beginning at 8:30 am ET. The event is being held in New York, NY.

October 4, 2018
·
3 min read
Genetown

AMAG Pharmaceuticals and Endoceutics Announce Presentation at the 2018 Annual Meeting of The North American Menopause Society on the Effect of Time Since Menopause, Age and Previous Hormone Therapy on the Response to Intravaginal Prasterone

Study Suggests that While All Postmenopausal Women Benefit from Treatment with Prasterone (INTRAROSA®), Women Experience Greatest Relief of Moderate to Severe Dyspareunia when started on INTRAROSA® within One to Two Years after Menopause

October 4, 2018
·
8 min read
Job Trends

Curantis Solutions Announces Palliative Care Solution to Improve Palliative Care Delivery and Access

Curantis Solutions, LLC, the software solutions company focused exclusively on serving the hospice and palliative care sector, announces the imminent release of its palliative care solution to the industry and is engaged in discussions with prospective clients.

October 4, 2018
·
2 min read
Business

AGAT Software Joins BlackBerry’s ISV Partner Program

SphereShield integration with BlackBerry UEM enables secure access to Skype for Business on mobile devices

October 4, 2018
·
3 min read
Pharm Country

Innovatus Life Sciences Announces Investment in Personal Genome Diagnostics

Innovatus Capital Partners, LLC (“Innovatus” or the “Firm”), an independent adviser and portfolio management firm with approximately $1.6 billion in assets under management, today announced that it has entered into a financing agreement with Personal Genome Diagnostics, Inc.

October 4, 2018
·
3 min read